ICT01 targets BTN3A (also known as CD277), which is physiologically expressed on the surface of innate and adaptive immune cells (including T and NK cells). Furthermore, BTN3A is found overexpressed on a number of solid tumors (e.g., PDAC, breast cancer, gastric, ovarian) and blood cancers (e.g., AML). BTN3A is essential for the activation of the anti-tumor activity of γ9δ2 T cells in response to the intracellular accumulation of phosphoantigens (pAgs), a set of small organic pyrophosphates produced both by stressed cells (i.e., malignant or infected cells).
ICT01 is an activating mAb targeting the extracellular domain of BTN3A that leads to activation and trafficking of γ9δ2 T cells out of the circulation. ICT01 has been shown to promote an anti-tumor immune response against a range of cancers in in vitro and in mouse tumor models. In primates, ICT01 rapidly occupies its target and specifically activates γ9δ2 T cells with a good safety profile that supports clinical testing.